ENTITY
WuXi XDC Cayman

WuXi XDC Cayman (2268 HK)

122
Analysis
Health CareChina
WuXi XDC Cayman Inc. operates as a leading contract testing, development and manufacturing organization focused on the global antibody drug conjugates and broader bioconjugate market. The Company provides bioconjugation discovery, analytical development, intermediate and conjugation manufacturing, and other services. WuXi XDC Cayman provides its services worldwide.
more
bullishWuXi XDC Cayman
07 Nov 2023 06:08

WuXi XDC IPO Preview: The Rapid Rise of The Business In The Global ADC and Bioconjugate Market

WuXi XDC filed to go public in Hong Kong. A rare combination of explosive growth and profitability makes the IPO attractive for investors

Logo
521 Views
Share
bullishWuXi XDC Cayman
06 Nov 2023 21:16

WuXi XDC IPO: Valuation First-Look

WuXi XDC is pre-marketing an HKEx IPO to raise US$500m. In this note, we present our forecasts and take the first look at the potential valuation...

Logo
669 Views
Share
bullishWuXi XDC Cayman
06 Nov 2023 14:19

WuXi XDC Cayman Pre-IPO - BULL/BEAR Scenario Considerations for Valuations

WuXi XDC Cayman (1877628D HK) is looking to raise around US$500m in its upcoming Hong Kong IPO. In this note, we share our updated thoughts on...

Logo
549 Views
Share
bearishOrigin Energy
05 Nov 2023 15:44

Weekly Deals Digest (05 Nov) - Origin, Azure, Tietto, Eoflow, Hollysys, WuXi XDC, Midea, EcoPro Mat

Last week, notable developments occurred in Event-Driven (Azure, Origin, Symbio, Tietto, Eoflow, Hollysys, NWS, Poly Culture, UMW) and ECM (EcoPro...

Logo
546 Views
Share
bullishWuxi Biologics
05 Nov 2023 08:25

ECM Weekly (5th Nov 2023)- Midea, WuxiXDC, Cello, Honasa, Qyuns, Ecopro, Lalatech, Mankind, TWE, VNT

Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.

Logo
536 Views
Share
x